Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. (Q54466780)

30 May 2018

title

Potent protective cellular immune responses generated by a DNA vaccine encoding HSV-2 ICP27 and the E. coli heat labile enterotoxin. (English)

1 reference

30 May 2018

0 references

1 reference

4

1 reference

30 May 2018

author name string

Joel R Haynes

1

1 reference

30 May 2018

Joshua Arrington

2

1 reference

30 May 2018

Lichun Dong

3

1 reference

30 May 2018

Lendon G Payne

5

1 reference

30 May 2018

language of work or name

English

0 references

publication date

31 March 2006

1 reference

30 May 2018

published in

Vaccine

1 reference

30 May 2018

volume

24

1 reference

30 May 2018

issue

23

1 reference

30 May 2018

page(s)

5016-5026

1 reference

30 May 2018

DNA-based immunotherapy: potential for treatment of chronic viral hepatitis?

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Progress on new vaccine strategies against chronic viral infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Recent progress in herpes simplex virus immunobiology and vaccine research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Molecular aspects of herpes simplex virus I latency, reactivation, and recurrence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Changing epidemiology of genital herpes simplex virus infection in Melbourne, Australia, between 1980 and 2003

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Why do we lack an effective vaccine against herpes simplex virus infections?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

CD8(+) T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Protective and pathological roles of virus-specific and bystander CD8+ T cells in herpetic stromal keratitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Herpes Simplex Virus-Specific Memory CD8+ T Cells Are Selectively Activated and Retained in Latently Infected Sensory Ganglia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Viral subversion of the immune system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

A cytosolic herpes simplex virus protein inhibits antigen presentation to CD8+ T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

CD8 CTL from genital herpes simplex lesions: recognition of viral tegument and immediate early proteins and lysis of infected cutaneous cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Monophosphoryl lipid A and QS21 increase CD8 T lymphocyte cytotoxicity to herpes simplex virus-2 infected cell proteins 4 and 27 through IFN-gamma and IL-12 production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Induction of protective immunity against herpes simplex virus with DNA encoding the immediate early protein ICP 27.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

The dual role of CD8+ T lymphocytes in the development of stress-induced herpes simplex encephalitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Particle-mediated DNA vaccine delivery to the skin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

A simple and efficient method for the monitoring of antigen-specific T cell responses using peptide pool arrays in a modified ELISpot assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Immunization with a LEAPS heteroconjugate containing a CTL epitope and a peptide from beta-2-microglobulin elicits a protective and DTH response to herpes simplex virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Incomplete effector/memory differentiation of antigen-primed CD8+ T cells in gene gun DNA-vaccinated mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

On T cell memory: arguments for antigen dependence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Differential biological and adjuvant activities of cholera toxin and Escherichia coli heat-labile enterotoxin hybrids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Comparative analysis of the mucosal adjuvanticity of the type II heat-labile enterotoxins LT-IIa and LT-IIb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Distinct cytokine regulation by cholera toxin and type II heat-labile toxins involves differential regulation of CD40 ligand on CD4(+) T cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Epidermal DNA vaccine for influenza is immunogenic in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

inferred from DOI database lookup

7 January 2021

based on heuristic

Immunization with a single major histocompatibility complex class I-restricted cytotoxic T-lymphocyte recognition epitope of herpes simplex virus type 2 confers protective immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.03.046

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2006.03.046

1 reference

30 May 2018

1 reference

30 May 2018